APC-100 prevents the occurrence or recurrence of prostate cancer, the company claims.
The drug is an orally available anti-androgenic/anti-inflammatory, signal transduction inhibitor which is said to have high therapeutic activity.
Notice of Allowance, which is the final step in the issuance of a patent, is believed to enhance the company’s patent portfolio for the use of APC-100.
APC-100 is part of an ongoing Phase 1/2a clinical prostate study that began in August.